If you have been ill for a long time, have been told your tests are negative, or have completed standard antibiotic treatment without recovering — you have likely encountered the name ILADS. For many patients, it represents the first moment that someone with medical credentials took their experience seriously.
This page explains what ILADS is, where it came from, what its guidelines actually say, and how treatment under an ILADS-informed physician typically differs from the standard approach. It is not a promotion of ILADS, and it is not an argument against it. It is an honest account of a medical organisation that matters to a great many patients.
What ILADS is
ILADS — the International Lyme and Associated Diseases Society — is a nonprofit, multidisciplinary medical society founded in 1999. Its members include physicians, scientists, and researchers from across the world, united by a shared clinical concern: that the current mainstream approach to diagnosing and treating Lyme disease and associated tick-borne infections is inadequate for a significant number of patients.
A professional medical organisation that publishes its own clinical guidelines, hosts international scientific conferences, trains physicians, and advocates for patients and research. It is peer-reviewed, physician-led, and grounded in published scientific literature — including the same microbiological research on Borrelia biology that the broader scientific community produces.
ILADS is not an alternative medicine organisation. It does not promote unproven therapies or reject conventional medicine. Its members are licensed medical doctors who use antibiotics — often the same antibiotics as standard guidelines — but apply them differently, for longer, and with greater attention to co-infections and individual clinical response.
ILADS members include internists, infectious disease specialists, neurologists, integrative physicians, and researchers. Many have backgrounds in academic medicine and have published in peer-reviewed journals. The organisation is not defined by a single discipline — it is defined by a clinical commitment to patients who are not improving under standard care.
Why ILADS exists — and why there is a debate at all
To understand ILADS, you need to understand the controversy it emerged from. This is not a story of science versus pseudoscience. It is a story of two groups of credentialed scientists who look at the same evidence and reach different conclusions — with patients caught in the middle.
The Infectious Diseases Society of America — whose guidelines most mainstream physicians follow — holds that Lyme disease is reliably diagnosed by the two-tier testing system (ELISA followed by Western blot), and that a short course of antibiotics is curative in the vast majority of cases. Persistent symptoms after treatment are attributed to post-infectious immune responses or other non-infectious causes, not ongoing active infection. Extended antibiotic courses are considered unsupported by the evidence and potentially harmful.
ILADS holds that current testing misses a clinically significant proportion of infected patients, that Borrelia is capable of persisting despite standard antibiotic courses (supported by the microbiological evidence on cysts, biofilms, and persisters), that co-infections are systematically undertested and undertreated, and that clinical judgement must be prioritised over negative test results when a patient's presentation is consistent with tick-borne illness. Extended or combination antibiotic treatment is considered appropriate and evidence-informed in certain clinical scenarios.
For patients, this debate has real and serious consequences. It means some people are told their illness does not exist, or that they have already been treated and therefore cannot still be ill. It means physicians who treat Lyme more aggressively have faced professional and legal pressure in certain jurisdictions — pressure that has made some reluctant to take on complex Lyme cases at all. Understanding the political dimension of this debate is part of navigating it.
The debate between IDSA and ILADS is not a debate between doctors and non-doctors. It is a debate between two groups of doctors who disagree about the interpretation of evidence — and the patients most affected are those with complex, persistent, or seronegative presentations.
Core clinical principles of the ILADS approach
ILADS published its evidence-based clinical practice guidelines most recently in updated form in 2014 (Cameron et al., Expert Review of Anti-infective Therapy). These guidelines outline a set of principles that distinguish the ILADS approach from standard care.
- Clinical diagnosis first — In Lyme disease, the clinical presentation — symptoms, history, exposure risk, physical findings — is considered the primary basis for diagnosis. A negative test result does not rule out infection. The ILADS guidelines explicitly state that testing should support clinical reasoning, not replace it. This is a fundamental departure from mainstream practice, where a negative ELISA typically ends the Lyme diagnostic conversation.
- Treatment duration based on response — Rather than a fixed 14–21 day course, ILADS guidelines support treatment for as long as the patient is showing clinical improvement — and reassessment when improvement plateaus. The end of treatment is determined by the patient's response, not by a calendar.
- Co-infections as central, not peripheral — ILADS treats co-infections — Bartonella, Babesia, Ehrlichia, Anaplasma, Mycoplasma — as a core part of the diagnostic and treatment picture, not an afterthought. The guidelines recognise that treating Borrelia alone when other pathogens are present is likely to produce incomplete recovery.
- Individualised treatment — No two patients are identical. Age, immune status, duration of illness, co-infections present, prior treatment history, and individual tolerance all inform the treatment plan. ILADS clinicians tend to treat the patient in front of them rather than applying a protocol uniformly.
- Informed consent and shared decision-making — ILADS guidelines emphasise that patients should be fully informed of the uncertainties in this field, the risks and benefits of extended treatment, and the alternatives — and that treatment decisions should be made collaboratively.
- Recognising the Herxheimer reaction — A temporary worsening of symptoms following the start of antibiotic treatment — commonly called a Herx — is recognised by ILADS clinicians as a potential indicator of pathogen die-off. It is managed carefully, not taken as a reason to stop treatment prematurely.
How ILADS-informed treatment works in practice
An ILADS-informed physician approaches a Lyme case differently from the first appointment. The following describes typical elements of this approach — not a fixed protocol, since ILADS explicitly discourages one-size-fits-all treatment.
An ILADS clinician will typically spend significant time on history: when symptoms began, what they include, how they fluctuate, what makes them better or worse, any known tick exposure, previous diagnoses, and previous treatments. The timeline of illness — often spanning years — is treated as clinically meaningful data, not background noise.
Beyond the standard two-tier ELISA and Western blot, ILADS clinicians often use specialised laboratories — including IGeneX, Vibrant America, or Galaxy Diagnostics — that test for a broader range of Borrelia species and strains, and that apply different criteria for a positive result. Co-infection panels for Bartonella, Babesia, Ehrlichia, Anaplasma, and Mycoplasma are standard. The results of all tests are interpreted in the context of the clinical picture, not in isolation.
A thorough assessment of all body systems — neurological, cardiovascular, musculoskeletal, cognitive, gastrointestinal — helps map which areas are most affected and which co-infections may be contributing. This systemic view often produces a coherent picture where previous specialist visits produced only fragments.
- Monotherapy or combination antibiotics — Depending on the presentation, an ILADS clinician may prescribe a single antibiotic or a combination targeting different bacterial forms — for example, doxycycline (targeting active spirochetes) combined with a drug active against cysts (such as tinidazole or metronidazole) and a drug targeting biofilms or intracellular forms (such as azithromycin or rifampin). The rationale is that no single drug addresses all forms of Borrelia simultaneously.
- Pulsed dosing — Some ILADS clinicians use pulsed antibiotic protocols — cycling antibiotics on and off on a weekly basis — based on the theory that Borrelia's slow replication cycle means it may be most vulnerable during certain phases, and that continuous dosing selects for resistance while pulsed dosing does not.
- Co-infection-specific drugs — Babesia requires anti-parasitic agents (atovaquone, artemisinin) rather than antibiotics. Bartonella responds better to macrolides (azithromycin, clarithromycin) or rifampin. Addressing each pathogen specifically — rather than hoping one antibiotic covers all — is central to the ILADS approach.
- Supportive care alongside antibiotics — Gut health, detoxification support, sleep, nutrition, and immune support are considered part of treatment — not optional extras. Antibiotic courses that damage the gut microbiome without concurrent restoration are seen as counterproductive over the long term.
- Regular reassessment — Treatment is not set and forgotten. ILADS clinicians typically schedule regular follow-up to assess response, adjust medications, rotate antibiotics if tolerance or effectiveness changes, and reconsider the diagnosis if improvement stalls unexpectedly.
Long-term antibiotic use carries real risks: disruption of the gut microbiome, potential for antibiotic resistance, hepatic strain, and side effects that can be difficult to distinguish from Lyme symptoms themselves. An ILADS clinician who is practising responsibly will discuss these risks explicitly, monitor liver function and blood counts, and use the minimum effective treatment rather than the maximum possible. If a practitioner does not discuss risks, that is a reason to ask more questions.
Finding an ILADS-informed clinician
Access to ILADS-informed care varies significantly by country and region. In the United States, there is a relatively larger network of Lyme-literate physicians. In Europe and elsewhere, they are fewer and often harder to reach — though the situation is gradually improving.
The most direct starting point is the ILADS website (ilads.org), which maintains a searchable directory of member physicians. Not all ILADS members are equally experienced — the directory is a starting point for your own research, not a quality endorsement of every listed practitioner.
Lyme patient communities — both national organisations and online groups — often maintain informal lists of recommended clinicians in their region, gathered from patient experience. This kind of peer knowledge can be more current and specific than any official directory. Treat it as one input among several, not a guarantee.
Ask how the clinician approaches co-infection testing. Ask what their criteria are for starting or extending treatment. Ask how they monitor for side effects. Ask what they do when a patient is not improving. The answers reveal whether you are seeing someone who treats the disease as a complex, evolving picture — or someone applying a fixed template.
ILADS-affiliated physicians frequently practise outside standard insurance frameworks — particularly in countries where Lyme guidelines are strict and extended treatment is not reimbursed. This is a real barrier for many patients, and acknowledging it honestly is more useful than ignoring it. If direct access to an ILADS clinician is not possible, telemedicine options have expanded significantly in recent years for initial consultations and guidance.
Where to go next
Many people use herbal protocols alongside ILADS antibiotic treatment — targeting different forms of Borrelia, supporting detoxification, and managing co-infections. Understanding the landscape of herbal approaches helps you have an informed conversation about them.
ILADS clinicians often use specialised testing laboratories. Understanding how different tests work — and what they are designed to find — helps you understand why results can differ between labs.
Before exploring treatment options in depth, understanding what the standard approach is — and where its limits appear — provides essential context for what ILADS is responding to.
Healing mentality checkpoint
Finding out that a different medical framework exists — one that takes your experience seriously — can bring enormous relief. It can also bring frustration that it took so long to find. Both responses are completely understandable. The information you are building now is not wasted time. It is the foundation for better conversations with any clinician you see next.
Read about healing mentality →A note on this information
- This page describes the ILADS approach as an educational overview — not as a recommendation for your specific situation.
- ILADS guidelines are one evidence-informed framework among several. Understanding them is not the same as choosing them.
- Any change to your treatment should involve a qualified clinician who knows your full picture.
- If you cannot access an ILADS clinician, the information here still equips you to ask better questions of whoever you can access.
Knowing that a different framework exists is not a diagnosis, and it is not a treatment plan. It is a door — and you decide whether and how to open it.
Sources & further reading
- Cameron D.J. et al. — Evidence assessments and guideline recommendations in Lyme disease (Expert Rev Anti Infect Ther, 2014) — the current ILADS guidelines
- Burrascano J.J. — Advanced topics in Lyme disease: diagnostic hints and treatment guidelines (ILADS, 2008)
- Horowitz R. — Why Can't I Get Better? Solving the Mystery of Lyme and Chronic Disease (2013)
- Johnson L., Stricker R.B. — The IDSA Lyme guidelines: a critically flawed document (Expert Rev Anti Infect Ther, 2010)
- Stricker R.B., Johnson L. — Lyme disease: the next decade (Infect Drug Resist, 2011)
- ILADS — ilads.org
- LymeSci research summary — lymedisease.org/lymesci
Last updated: March 2026